# Evaluating the Efficacy and Safety of Bevacizumab, Carboplatin, Gemcitabine and Atezolizumab in Breast Cancer

> **NCT04739670** · PHASE2 · UNKNOWN · sponsor: **Peter MacCallum Cancer Centre, Australia** · enrollment: 31 (estimated)

## Conditions studied

- Metastatic Triple Negative Breast Cancer

## Interventions

- **DRUG:** Atezolizumab
- **DRUG:** Bevacizumab
- **DRUG:** Gemcitabine
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT04739670
- **Lead sponsor:** Peter MacCallum Cancer Centre, Australia
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-03-01
- **Primary completion:** 2025-09
- **Final completion:** 2025-09-30
- **Target enrollment:** 31 (ESTIMATED)
- **Last updated:** 2024-03-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04739670

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04739670, "Evaluating the Efficacy and Safety of Bevacizumab, Carboplatin, Gemcitabine and Atezolizumab in Breast Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04739670. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*